Table 3.
Intra-operative findings, distribution of cervical dilatation and complications by randomised treatment group
Dosage group |
P | ||
---|---|---|---|
Self-administered vaginal placebo (n = 34) | Self-administered vaginal misoprostol (n = 33) | ||
Cervical dilatation at hysteroscopy (mm), mean (SD) | 4.7 (1.5) | 5.7 (1.6) | 0.01 |
Baseline cervical dilatation (mm) at inclusion, mean (SD) | 2.1 (1.7) | 2.6 (1.7) | |
Mean difference in cervical dilatation (mm) between inclusion and hysteroscopy (SD) | 2.7 (1.7) | 3.1 (1.9) | |
Number of patients achieving cervical dilatation ≥5 mm, n (%) | 20 (59) | 30 (88) | |
‘Difficult dilatation’, n (%) | 7 (21) | 1 (3) | |
Exposure to capsules (min), mean (SD) | 726 (109) | 750 (84) | |
Frequency of preoperative complications, n (%) | 1 (3) | 1 (3) | |
Complications within 14 days after hysteroscopy, n (%) | 0 | 0 |